Back to search

Article

IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodies

2022-06-10

Abstract excerpt

Anti-CD20 monoclonal antibodies such as Rituximab, Ofatumumab and Obinutuzumab are widely used to treat lymphomas and autoimmune diseases. They act by depleting B cells, mainly through Fc-dependent effectors functions. Some patients develop resistance to treatment but the underlying mechanisms are poorly understood. Here, we performed a genome-wide CRISPR/Cas9 screen to identify genes regulating the efficacy of an...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
91c03757-6f6f-5def-a150-28fbb8b7a9f8
DOI
10.1101/2022.06.09.495444
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
IRF8 regulates efficacy of therapeutic anti-CD20 monoclonal antibodiesDOI 10.1101/2022.06.09.495444
IRF8 regulates efficacy of therapeutic anti‐CD20 monoclonal antibodiesSemantic proximity
Single-cell level characterization of B cell depletion and repopulation following rituximab in systemic lupus erythematosusSemantic proximity
Comprehensive genetic and functional analysis of FcγRs in rituximab therapy for autoimmunity reveals a key role for FcγRIIIa on NK cellsSemantic proximity
Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector MechanismsSemantic proximity
Complement-Induced Cell Death by Rituximab Depends on CD20 Expression Level and Acts Complementary to Antibody-Dependent Cellular CytotoxicitySemantic proximity
Identification of BLNK and BTK as mediators of rituximab-induced programmed cell death by CRISPR screens in GCB-subtype diffuse large B-cell lymphoma.Semantic proximity
Cellular Cytotoxicity of Next-Generation CD20 Monoclonal AntibodiesSemantic proximity
Rituximab resistance.Semantic proximity
The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapySemantic proximity
FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapySemantic proximity
Macrophage-mediated antibody dependent effector function in aggressive B-cell lymphoma treatment is enhanced by Ibrutinib via inhibition of JAK2Semantic proximity
High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism.Semantic proximity
Select a neighboring publication to make it the new centre.